Pfizer revealed that it has recently filed applications with the regulators in the U. S., Europe and Canada in a view to get its Sutent approved for treating a rare type of pancreatic cancers.

The form of pancreatic cancer, called pancreatic neuroendocrine tumours, are marginally rare, engulfing two to four people per million annually worldwide, claimed the National Cancer Institute. An expanded approval to treat the disease would likely not add significantly to Sutent revenue.

In the most recent study of patients with advanced tumours originating in the hormone-production area of the pancreas, revealed the drug delayed worsening of the pancreatic cancer by almost six months longer than a placebo.

The positive results have prompted the world's largest drug maker to halt the trial early, were considered highly statistically significant.

Sutent, bearing a chemical name as sunitinib, is currently allowed to treat advanced kidney cancer and gastrointestinal stromal tumor, a cancer of the digestive system.

Sutent is attributed as Pfizer's fastest-growing brands reporting a third quarter sales of $246 million, and is being studied in a number of other types of solid tumours as well.

The most common side effects posed by taking Sutent are low white blood cells, high blood pressure, abdominal pain, diarrhoea, low blood sugar and swelling of the hands and feet.

Pfizer shares were up 2 cents at $19.26 in morning trade on the New York Stock Exchange.